Abstract 5066
Background
Receiving a diagnosis of cancer may be associated with increased psychosocial distress. Without objective assessments, healthcare professionals tend to underestimate psychological distress, and fail in the recognition, triage and referral of distressed patients. The specific aims of this study are to identify the level and the nature of the distress.
Methods
A descriptive prospective design has been used to analyze the data of distress thermometer (DT) in initial visits in the cancer unit. Data collection was conducted by nurses over a six month period. The variables studied were: age, sex, type of tumor, intensity and causes of distress.
Results
39 patients answered the DT screening tool. On average, the participants were 58.1 years old and 64% of them were female. The most frequent diagnoses reported were breast cancer (38%) and colon cancer (26%). 41 % rated over the cut point of DT (>4) and were referred to psycho-oncology attention. Only the 48 % attended to the psychologist after referral despite the most frequent causes of distress were physical problems (85%) and emotional problems (70%). Finally, there were a statistically significant association between intensity of distress and emotional problems (r = 0,648; p < 0, 001) but not with other problematic areas (physical, family, spiritual or practical).
Conclusions
Psychosocial distress in recently diagnosed cancer patients seems to be related with emotional problems. It is important to evaluate and manage emotional distress in these patients to improve their quality of life and refer patients to the psychologist when it is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E Bailles.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract